Sysmex Inostics is a pioneering leader in the field of liquid biopsy, offering advanced testing solutions that leverage circulating free DNA (cfDNA) and circulating free RNA (cfRNA) for drug discovery, therapy selection, and treatment response monitoring. Their extensive portfolio includes broad panel assays that can sequence over 200 gene targets at a depth of 20,000X, allowing for the identification of novel biomarkers and comprehensive variant monitoring. Additionally, they provide targeted panel assays with a focus on ultra-low frequency mutations, ensuring high sensitivity and specificity. Their digital PCR (dPCR) technology allows for rapid results with minimal sample preparation, making it an effective tool for monitoring treatment responses and patient stratification.

In collaboration with QIAGEN, Sysmex Inostics accelerates companion diagnostic (CDx) development, enhancing the clinical trial process for biopharma clients. Their commitment to providing seamless end-to-end solutions is supported by exceptional project management, ensuring that clients receive tailored support throughout all phases of clinical trials. By integrating their advanced molecular assays and project management expertise, Sysmex Inostics aims to expedite drug discovery and development, ultimately contributing to improved treatment options for cancer patients.

United States

Sysmex Inostics is a medical diagnostics company that specializes in cancer testing through liquid biopsy technology, catering to precision medicine.

Sysmex Inostics

Company Details